Q-omics provides the consensus-scored ARG2 profile across patient tissues and cancer cell-line models. ARG2 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, ARG2 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, ARG2 RNA expression shows 18,772 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and KIRC as cancer lineages where ARG2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ARG2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ARG2 survival associations across molecular data types. ARG2 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (1) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ARG2 RNA expression–survival associations across cancer types. High ARG2 expression shows unfavorable associations in UVM, SARC and STAD, but favorable associations in BRCA, PAAD and KIRC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for ARG2 RNA expression.
This table summarizes ARG2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for ARG2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ARG2 shows lower tumor expression in KIRC, KIRP, THCA and KICH and higher tumor expression in COAD and LUAD. The KIRC box plot shows higher ARG2 RNA expression in normal versus tumor tissue (log2 FC = −3.006, t-test p < 0.001).
This table shows molecular features associated with ARG2 in patient tissues and cancer cell lines. In patient samples, ARG2 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ARG2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and BLOOD_Leukemia.
